ClinicalTrials.gg
RecruitingNCT04832776Updated Apr 6, 2021

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

A Phase 2 interventional study of Cetuximab and Bevacizumab in Liver Metastasis Colon Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies testing cetuximab in Colonic Neoplasms — 7 open to participants now, 12 under way, 4 of them phase 3. Cetuximab · Colonic Neoplasms.

Planned enrollment
13th of 56
160 · median 46
Started
2021
with 2 others
Phase 2
34 of 58
5 open now
Primary completion
2023-12
later than 0 of 11 live
Registered
50th of 58
by date

Among the 58 studies testing cetuximab in Colonic Neoplasms, this one is the 13th largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2021, is one of 34 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 50th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

7 of the 58 studies testing cetuximab in Colonic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing cetuximab in Colonic Neoplasms, or all of them as a file.
02

Study summary

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

03

Conditions studied

  • Liver Metastasis Colon Cancer

Keywords

  • FOLFOXIRI
  • cetuximab
  • bevacizumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • perfomance 0-1
  • confirmed colorectal carcinoma, with RAS wild type
  • inital unresectable liver discussed by MDT
  • prior no systemical therapy or exceed 6 months after the chemotherapy of primary tumor surgery.
  • without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
  • adequate blood, liver and renal function
  • expected survival longer than 6 months

Exclusion criteria

Exclusion Criteria:

  • with bleeding risk
  • interestinal obstruction or disease
  • uncontrolled hypertension and severe heart disease
  • previous severe thrombotic events
  • central nervous system
  • accompanied with other malignant tumor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    FOLFOXIRI+C225

    Drug: Cetuximab · Drug: FOLFOXIRI

  • Active comparator
    FOLFOXIRI+BEV

    Drug: Bevacizumab · Drug: FOLFOXIRI

Interventions

  • one group plus cetuximab

  • one group plus bevacizumab

  • DrugFOLFOXIRI

    FOLFOXIRI

06

What researchers measure

Primary outcomes

  1. ORR

    objective response rate

    Time frame: up to 8 weeks

Secondary outcomes

  1. R0 resection rate of liver metastases

    R0 resection rate of liver metastases

    Time frame: up to 8 weeks

  2. NED rate

    percentage of patients who reach NED

    Time frame: up to 8 weeks

  3. OS

    overal survival

    Time frame: up to 6 months

  4. PFS

    progression free survival

    Time frame: up to 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2021; primary completion for Dec 2023, 32 months later.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 32 months is below that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2021
First posted
Apr 6, 2021
StartEst.
Apr 17, 2021
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2025
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04832776
Lead sponsor
Fudan University
Responsible party
Sanjun Cai (Department of Colorectal Surgery, Fudan University) — Principal investigator
First posted
Apr 6, 2021
Start date
Apr 17, 2021 (estimated)
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 6, 2021

Study contacts

Wenhua Li
Contact
whliiris@hotmail.com
13817922257 ext. 13817922257
Wen Zhang
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion